1. Metabolic Enzyme/Protease
  2. Phospholipase
  3. Tanshinone I

Tanshinone I  (Synonyms: 丹参酮I; Tanshinone A)

目录号: HY-N0134 纯度: ≥98.0%
COA 产品使用指南 技术支持

Tanshinone I 是一种IIA型人重组 sPLA2 和兔重组 cPLA2 抑制剂,IC50 分别为 11 μM 和 82 μM。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Tanshinone I Chemical Structure

Tanshinone I Chemical Structure

CAS No. : 568-73-0

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
5 mg ¥400
In-stock
10 mg ¥570
In-stock
25 mg ¥900
In-stock
50 mg ¥1170
In-stock
100 mg ¥1521
In-stock
500 mg ¥3340
In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Tanshinone I:

查看 Phospholipase 亚型特异性产品:

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Tanshinone I is an inhibitor of type IIA human recombinant sPLA2 (IC50=11 μM) and rabbit recombinant cPLA2 (IC50=82 μM).

IC50 & Target

IC50: 11 μM (sPLA2), 82 μM (cPLA2)[1].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
AGS IC50
> 50 μM
Compound: 6, tanshinone i
Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay
Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay
[PMID: 17583950]
AGS IC50
12.5 μM
Compound: 6, tanshinone i
Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay
Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay
[PMID: 17583950]
Hep 3B2 EC50
> 10 μM
Compound: 3
Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
[PMID: 20455578]
Hep 3B2 IC50
> 50 μM
Compound: 6, tanshinone i
Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay
Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay
[PMID: 17583950]
Hep 3B2 IC50
8.51 μM
Compound: 6, tanshinone i
Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay
Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay
[PMID: 17583950]
HepG2 EC50
> 10 μM
Compound: 3
Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
[PMID: 20455578]
HepG2 EC50
6.3 μM
Compound: 3
Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay
Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay
[PMID: 20455578]
KB IC50
5.87 μM
Compound: 1
Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
[PMID: 29294282]
MCF7 IC50
7.927 μM
Compound: 1
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 33751939]
MDA-MB-231 IC50
7.962 μM
Compound: 1
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 33751939]
MIA PaCa-2 IC50
10.5 μM
Compound: 15
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay
[PMID: 21775156]
PLC-PRF-5 EC50
> 10 μM
Compound: 3
Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay
Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay
[PMID: 20455578]
Vero C1008 CC50
> 200 μM
Compound: 29
Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay
Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay
[PMID: 35620927]
体外研究
(In Vitro)

Tanshinone I 抑制脂多糖 (LPS) 诱导的 RAW 巨噬细胞中前列腺素 E2 (PGE2) 的形成 (IC50=38 μM) 。当Tanshinone I 与 LPS 同时加入时,10-100 μM 浓度下可明显抑制 PGE2 的产生 (IC50=38 μM) 。在 COX-2 完全诱导后加入 Tanshinone I,也可降低 PGE2 的产生 (IC50=46 μM) 。当 Tanshinone I 与两种不同形式的磷脂酶 A2 (PLA2) 一起孵育时,它以浓度依赖的方式明显抑制分泌型磷脂酶 A2 (sPLA2) (IC50=11 μM) 。虽然抑制作用较弱,但 Tanshinone I也可抑制胞质型磷脂酶 A2 (cPLA2) (IC50=82 μM) [1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Tanshinone I 在大鼠角叉菜胶诱导的足肿胀和佐剂诱导的关节炎模型中表现出抗炎活性。口服Tanshinone I 对 CGN 诱导的足肿胀具有显著的抗炎活性 (160mg/kg 时抑制率为 47%) ,而 Indomethacin 的 IC50为 7.1mg/kg。在AIA 模型中,口服剂量为 50mg/kg/天时,Tanshinone I 在第 18 天对继发性炎症的抑制率为 27% ,而Prednisolone (5mg/kg/ 天) 的抑制作用较强 (65%) [1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

276.29

Formula

C18H12O3

CAS 号
性状

固体

颜色

Light brown to black

中文名称

丹参酮 I

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 2 mg/mL (7.24 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.6194 mL 18.0969 mL 36.1939 mL
5 mM 0.7239 mL 3.6194 mL 7.2388 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
纯度 & 产品资料

纯度: ≥98.0%

参考文献
Kinase Assay
[1]

As sources of PLA2, human recombinant sPLA2 (type IIA) is purified from CHO cells transfected with the PLA2 gene and rabbit recombinant platelet cPLA2 is obtained through its expression in baculovirus. The standard reaction mixture (200 μL) contained 100 mM Tris-HCl buffer (pH 9.0) with 6 mM CaCl2 and 20 nmol 1-acyl-[1-14C]-arachidonyl-sn-glycerophosphoethanolamine (2000 cpm/nmol) in the presence or absence of Tanshinone I. The reaction is started by adding 50 ng purified sPLA2 or cPLA2. After 20 min at 37°C, the free fatty acid generated is analysed. Under these standard conditions, the reaction mixture in the absence of Tanshinone I released approximately 10% of free fatty acid from the phospholipid substrate added[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

RAW 264.7 cells are cultured with DMEM supplemented with 10% FBS and 1% antibiotics under 5% CO2 at 37°C. Briefly, cells are plated in 96-well plates (2×105 cells/well). LPS (1 ug/mL) and Tanshinone I are simultaneously added and incubated for 24 h, unless otherwise specified. The PGE2 concentration in the medium is measured using an EIA kit for PGE2. In order to determine the effects of Tanshinone I on PGE2 production after induction of COX-2, cells are incubated with LPS (1 ug/mL) for 24 h and thoroughly washed. Then, Tanshinone I is added without LPS and the cells are incubated for another 24 h. From the medium, PGE2 concentrations are measured. The cytotoxicity of Tanshinone I to RAW cells is checked using the MTT assay. Tanshinone I does not show any cytotoxicity up to 100 uM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]
In order to evaluate the inhibitory activity of Tanshinone I against animal models of acute and chronic inflammation, rat carrageenan (CGN)-induced paw oedema and adjuvant-induced arthritis (AIA) models are employed. Briefly, 1% CGN dissolved in pyrogen-free saline (0.05 mL) is injected into right hind paw of rats for the paw oedema test. After 5 h, swelling of the treated paw is measured using a plethysmometer. Tanshinone I dissolved in 0.5% CMC is administered orally 1 h prior to CGN injection. For the AIA test, an arthritic inflammation is provoked by injection of Mycobacterium Butyricum (0.6 mL/rat) dissolved in mineral oil to the right hind paw of rats. Tanshinone I is orally administered every day. The swelling of the treated and untreated paws is measured using a plethysmometer.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.6194 mL 18.0969 mL 36.1939 mL 90.4846 mL
5 mM 0.7239 mL 3.6194 mL 7.2388 mL 18.0969 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Tanshinone I
目录号:
HY-N0134
需求量: